BeiGene Stock Forecast, Price & News

BeiGene (NASDAQ:BGNE) Frequently Asked Questions

Is BeiGene a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BeiGene stock.
View analyst ratings for BeiGene or view top-rated stocks.

How has BeiGene's stock been impacted by COVID-19?

BeiGene's stock was trading at $145.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BGNE shares have increased by 138.7% and is now trading at $347.69.
View which stocks have been most impacted by COVID-19.

Are investors shorting BeiGene?

BeiGene saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 2,070,000 shares, a drop of 33.9% from the October 31st total of 3,130,000 shares. Based on an average trading volume of 235,600 shares, the short-interest ratio is presently 8.8 days.
View BeiGene's Short Interest.

When is BeiGene's next earnings date?

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for BeiGene.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($4.46) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($4.70) by $0.24. BeiGene had a negative trailing twelve-month return on equity of 35.06% and a negative net margin of 122.41%.
View BeiGene's earnings history.

What price target have analysts set for BGNE?

8 analysts have issued 12-month price objectives for BeiGene's stock. Their forecasts range from $190.00 to $431.00. On average, they expect BeiGene's share price to reach $356.88 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts' price targets for BeiGene or view top-rated stocks among Wall Street analysts.

Who are BeiGene's key executives?

BeiGene's management team includes the following people:

• John V. Oyler, Chairman & Chief Executive Officer (LinkedIn Profile)
• Xiao Bin Wu, President & Chief Operating Officer (LinkedIn Profile)
• Julia Wang, Chief Financial & Accounting Officer
• Jane E. Huang, Chief Medical Officer-Hematology
• Yong Ben, Chief Medical Officer-Immuno & Oncology Department

What is John V. Oyler's approval rating as BeiGene's CEO?

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

Who are some of BeiGene's key competitors?

Some companies that are related to BeiGene include Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Zoetis (ZTS), CSL (CSLLY), Regeneron Pharmaceuticals (REGN), Bayer Aktiengesellschaft (BAYRY), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Astellas Pharma (ALPMY), Genmab A/S (GNMSF), Genmab A/S (GMAB), Royalty Pharma (RPRX) and Shiseido (SSDOY).
View all of BGNE's competitors.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.55%), Primecap Management Co. CA (4.08%), Invesco Ltd. (3.28%), Temasek Holdings Private Ltd (3.12%), BlackRock Inc. (2.82%) and Wellington Management Group LLP (0.91%). Company insiders that own BeiGene stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for BeiGene.

Which institutional investors are selling BeiGene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Capital Bank & Trust Co, Goldman Sachs Group Inc., Wellington Management Group LLP, Bellevue Group AG, Macquarie Group Ltd., Primecap Management Co. CA, and Baillie Gifford & Co.. Company insiders that have sold BeiGene company stock in the last year include Bros Advisors Lp Baker, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for BeiGene or view top insider-selling stocks.

Which institutional investors are buying BeiGene stock?

BGNE stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Temasek Holdings Private Ltd, BlackRock Inc., BNP Paribas Asset Management Holding S.A., UBS Group AG, Deutsche Bank AG, Schonfeld Strategic Advisors LLC, and Caption Management LLC. Company insiders that have bought BeiGene stock in the last two years include Amgen Inc, and Ltd Beigene.
View insider buying and selling activity for BeiGene or or view top insider-buying stocks.

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $347.69.

How much money does BeiGene make?

BeiGene has a market capitalization of $32.47 billion and generates $308.87 million in revenue each year. The company earns $-1.60 billion in net income (profit) each year or ($14.20) on an earnings per share basis.

How many employees does BeiGene have?

BeiGene employs 5,300 workers across the globe.

When was BeiGene founded?

BeiGene was founded in 2010.

What is BeiGene's official website?

The official website for BeiGene is www.beigene.com.

Where are BeiGene's headquarters?

BeiGene is headquartered at 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 861058958000 or via email at [email protected].